1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. EMCURE PHARMACEUTICALS LTD.
Emcure Pharmaceuticals Ltd.
NSE: EMCURE | BSE: 544210

Emcure Pharma Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutEmcure Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in India with a significant global presence, particularly in the domestic, European, and Canadian markets. The company specializes in developing, manufacturing, and m... Read More
Ask AI about Emcure Pharma
1871.806.80(0.36%)

43.27% Gain from 52W Low

84,676
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Emcure Pharma is on 03 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
55.5 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

19

S

4

W

8

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive7Negative

Pass in checklist68.2%

045
55
100

Check P/E Buy Sell Zone

Neutral Zone

41.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Emcure Pharma Stock Price Analysis

Day Price Range

0.4% 1 Day return
1871.8 (LTP)
1,852.61,887
LowHigh

Week Price Range

5.7% 1 Week return
1871.8 (LTP)
1,7511,889.2
LowHigh

Month Price Range

-4.5% 1 Month return
1871.8 (LTP)
1,7161,974
LowHigh

52 Week Price Range

39.9% 1 Year return
1871.8 (LTP)
1,306.52,100.7
LowHigh
View full Price History/Seasonality

Emcure Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Emcure Pharma's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

CURRENT EPS
48.8
AVG. ESTIMATE
62.7
LOW ESTIMATE
60.7
HIGH ESTIMATE
64.6
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 28.6% in FY27

Consensus Recommendation

8 ANALYST Recommendations
STRONG BUY

The consensus recommendation from 8 analysts for Emcure Pharma is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Emcure Pharma Technical Analysis

Emcure Pharma EMA & SMA

Bullish+6
7 bullish, 1 bearish
Bullish7
Bearish1
5 Day1853.7
10 Day1842.9
12 Day1843.6
20 Day1853.9
26 Day1861.8
50 Day1873.9
100 Day1842.2
200 Day1742.8

Emcure Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202659.4%
Week58.0%
Month63.0%

Emcure Pharma Active Candlesticks

Short Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Emcure Pharma Resistance and Support

1870.47
Pivot
First Resistance1888.3
Second Resistance1904.9
Third Resistance1922.7
First Support1853.9
Second Support1836.1
Third Support1819.5
Day RSI51.5
Day MACD-18.2
Day MFI49
Day MACD Signal Line-26.2

Emcure Pharma Beta

1 Month0.2
1 Year0.4
3 Month0.2
3 Year-

Emcure Pharma Price Change Analysis

↓-4.5%
Over 1 Month
LowHigh
17161974
↓-2.1%
Over 3 Months
LowHigh
17162100.7
↑8.2%
Over 6 Months
LowHigh
1627.42100.7
↑39.9%
Over 1 Year
LowHigh
1306.52100.7
All Technicals →

Emcure Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Satish R MehtaPromoter75,396,74839.7 %
Government Pension Fund GlobalFii2,000,0001.1 %
Kotak Midcap FundDii4,381,6252.3 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Emcure Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
BC INVESTMENTS IV LIMITEDBlockSell25 Jun 20261817969,730NSE
BC INVESTMENTS IV LIMITEDBlockSell25 Jun 20261817969,729NSE
AXIS MUTUAL FUNDBlockPurchase25 Jun 20261817137,591NSE
ALPHA ALTERNATIVES EQUITY ABSOLUTE RETURN FUNDBlockPurchase25 Jun 20261817137,593NSE
BNP PARIBAS FINANCIAL MARKETSBlockPurchase25 Jun 20261817137,592NSE
HDFC STANDARD LIFE INSURANCE COMPANY LTDBlockPurchase25 Jun 20261817556,954NSE
ADITYA BIRLA SUN LIFE MUTUAL FUNDBlockPurchase25 Jun 20261817261,420NSE
MORGAN STANLEY ASIA SINGAPORE PTEBlockPurchase25 Jun 20261817137,590NSE
HSBC MUTUAL FUNDBlockPurchase25 Jun 20261817137,590NSE
HDFC STANDARD LIFE INSURNACEBlockPurchase25 Jun 20261817157,949NSE
All deals

Emcure Pharma Corporate Actions

Emcure Pharma Dividend history and yield

Emcure Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Emcure Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
104 Sep 2026
3.6FINAL04 Sep 2026Equity Share
214 Aug 2025
3FINAL14 Aug 2025Equity Share

Emcure Pharma Board Meetings

Emcure Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
103 Nov 2026
Quarterly Results-
206 Aug 2026
Quarterly Results-
305 May 2026
Audited Results & Final Dividend-
404 Feb 2026
Quarterly Results-
511 Nov 2025
Quarterly Results-
All Corporate Actions

Emcure Pharma Research Reports

Emcure Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
120 Oct 2026Motilal Oswal
Target
23301755.1Buy32.76%6.65%pdf
203 Sep 2026ICICI Direct23051927.6Buy19.58%-2.89%pdf
306 Aug 2026Motilal Oswal
Target
23001936.7Buy18.76%-3.35%pdf
419 Jul 2026Motilal Oswal22601783.2Buy26.74%4.97%pdf
505 May 2026BOB Capital Markets Ltd.
Target
19651659.5Buy18.41%12.79%pdf
All Reports of Emcure

Emcure Pharma Corporate Filings

Emcure Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
14 Oct 2026
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for Earnings Call - Q2 FY27
PDF
14 Oct 2026
Emcure Pharmaceuticals Ltd - 544210 - Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2026
Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026
PDF
12 Oct 2026
Emcure Pharmaceuticals Ltd - 544210 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026
PDF
12 Oct 2026
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding Company, subject to requisite statutory and regulatory approvals.
PDF
02 Oct 2026
Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)
PDF
VIEW ALL

Emcure Pharma DocumentsAsk MarketMind AI

Emcure Pharma Earnings Call

Emcure Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
12 Aug 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
06 Aug 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
05 May 2026Emcure Pharmaceuticals Results Earnings Call for Q4FY26 & Full YearAudioVideo
10 Feb 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
17 Nov 2025Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Emcure Pharma Annual Reports

Emcure Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link

Emcure Pharma Credit Ratings

Emcure Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
30 Aug 2026care ratingsEmcure Pharmaceuticals LimitedLink
04 Dec 2025crisil ratingsEmcure Pharmaceuticals LimitedEmcure Pharmaceuticals Limited:Update on Emcure Pharmaceuticals LimitedLink
16 Oct 2025crisil ratingsEmcure Pharmaceuticals LimitedEmcure Pharmaceuticals Limited:Rating outlook revised to 'Positive'; Ratings ReaffirmedLink
06 Oct 2025care ratingsEmcure Pharmaceuticals LimitedLink
05 Nov 2024crisil ratingsEmcure Pharmaceuticals LimitedEmcure Pharmaceuticals Limited:Ratings ReaffirmedLink

Emcure Pharma Investor Presentations

Emcure Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
25 Sep 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Aug 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 Jun 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 May 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
20 Feb 2026Emcure Pharmaceuticals Ltd - 544210 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Emcure Pharma - Company Profile

Emcure Pharma Management Structure

Emcure Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Satish MehtaManaging Director,Chief Executive Officer3240.1Mar 26
Mr. Samit MehtaExecutive Director,Whole Time Director,Chief Operating Officer351.4Mar 26
Mr. Rajesh NairPresident(Human Resources)-Mar 26
Mr. Deepak GondaliyaPresident(Technical Operations)-Mar 26
Mr. Tajuddin ShaikhChief Financial Officer-Mar 26
Amruta YangalwarCompany Secretary,Compliance Officer-Mar 26
Mr. Sanjay MehtaPresident(Emerging Markets)-Mar 26
Mr. Vikas ThaparPresident(Corporate Development,Strategy.,Finance)-Mar 26
Mr. Srinivasan RaghavachariPresident(India Business Unit)-Mar 26
Mr. Kuber JagdalePresident(API Business)-Mar 26

Emcure Pharma Board of Directors

Emcure Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
SATISH RAMANLAL MEHTACMD & CEO2561.2Mar 25
MUKUND KESHAO GURJARWhole Time Director621.7Mar 25
NAMITA VIKAS THAPARWhole-time Director483.2Mar 25
SAMIT SATISH MEHTAWhole Time Director & COO343.4Mar 25
Shailesh AyyangarIndependent Director54.8Mar 25
Vijay GokhaleIndependent Director24.6Mar 25
Vidya Rajiv YeravdekarIndependent Director17Mar 25
Samonnoi BanerjeeNon Executive Director4.4Mar 25
Amruta Jana YangalwarCompany Sec. & Compli. Officer-Mar 25
RAMAN PILLAI RAGHU KUMARAdditional Director-Mar 25
Website: www.emcure.com

About the company - Business Profile

Emcure Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in India with a significant global presence, particularly in the domestic, European, and Canadian markets. The company specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical products across several major therapeutic areas, including gynaecology, cardiovascular, vitamins, minerals and nutrients, HIV/AIDS, and oncology. Emcure is recognized for its focus on differentiated and complex generics, leveraging its strong research and development (R&D) capabilities to address unmet medical needs. The company maintains a leading position in the Indian Pharmaceutical Market (IPM), specifically ranking as the largest player in gynaecology and holding a top 10 position in the covered markets.

Key Points

  • Key Facts: Founded in 1981 and headquartered in Pune, India, Emcure Pharmaceuticals Ltd. was listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on July 10, 2024. The company has evolved from a contract manufacturer to a global pharmaceutical entity.
  • Operations and Resources: The company operates multiple manufacturing facilities across India, with notable sites in Gujarat (Sanand and Mehsana), Maharashtra (Pimpri and Hinjewadi), and Sikkim. These facilities are approved by international regulatory bodies, including the USFDA and UK MHRA. In 2024, Emcure inaugurated a new Research Centre in Gujarat to bolster its R&D pipeline.
  • Ownership: Emcure is a promoter-led company, with the Mehta family holding a significant stake. Private equity firm Blackstone has been a long-term investor, though the company recently transitioned to a public listing.
  • Market Significance: Emcure is the 13th largest pharmaceutical player in India by domestic sales and the 4th largest in the gynaecology therapeutic area. Globally, it has a presence in over 70 countries, with specialized operations through subsidiaries like Marcan Pharmaceuticals in Canada and Manx Healthcare in the UK.
  • Sustainability and Innovation: The company focuses on biological and complex injectables. A significant milestone includes the development of India's first mRNA vaccine for COVID-19 by its subsidiary, Gennova Biopharmaceuticals.
  • Business Model: Emcure follows a research-driven business model focused on complex generics and differentiated products. It excels in gynaecology, HIV/AIDS, and oncology, utilizing a deep-rooted distribution network and physician-focused marketing.
  • Revenue Breakdown (FY2025):
    • Total Revenue from Operations: Rs. 7,896 crore.
    • Geographical Split: India (46.3%), Europe (18.7%), Canada/North America (15.9%), and Rest of World (19.1%).
  • Key Products and Technology: Anchor brands include Augpen (Antibiotic), Vintor (Renal), Encicarb (Iron), and Tenectase (Stroke management). Recent technology advancements include the launch of Poviztra, a biological injectable semaglutide for obesity management. The company has 14 brand families with annual revenue exceeding Rs. 50 crore each.
  • Partnerships and Contracts: A strategic partnership with Novo Nordisk has provided Emcure with an early-entry advantage in the anti-obesity segment. It also has a long-standing history of strategic acquisitions, such as Mantra Pharma in Canada (2024) to expand its generic footprint.
  • Employee Overview: As of the latest reports, the company employs a large workforce across its manufacturing, R&D, and sales functions, though specific current headcount and attrition rates were not detailed in the provided snippets.
  • Major Subsidiaries: Key units include Gennova Biopharmaceuticals (Biotherapeutics and vaccines), Marcan Pharmaceuticals (Canada), and Emcutix Biopharmaceuticals (Dermatology).
  • Strategic Initiatives: Emcure is currently focused on expanding its reach in gynaecology and oncology, scaling its consumer health (OTC) segment through the Arth brand, and driving growth in international markets through complex injectables.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Investor Presentation Feb 2026
  4. Earnings Results Feb 2026

Emcure Pharma FAQ

Emcure Pharma today is trading in the green, up by 0.36% at ₹1,871.8.
Emcure Pharma is currently trading up 0.36% on an intraday basis. In the past week the stock rose 5.73%. Stock has been down 2.05% in the past quarter and rose 39.91% in the past year. You can view this in the share price history/seasonality section.
Emcure Pharma is listed on NSE with the ticker EMCURE and on BSE as 544210. It's currently trading on NSE at a share price of ₹1,871.8 and on BSE with a share price of ₹1,862.
The market cap of Emcure Pharma is ₹35,510.03 Cr. as of Oct 30, 2026.
Emcure Pharma announced a FINAL dividend of 36% which equals ₹3.6 in Sep 04, 2026.The last ex-date for Emcure Pharma was Aug 14, 2025. To view the full dividend history of Emcure Pharma click here.
Emcure Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Emcure Pharma reported ₹2,582.52 Cr. in revenue, ₹293.98 Cr. in net profit, and ₹534.57 Cr. in EBITD as of Aug 06, 2026 for Q1 FY26-27.
According to the predictions of 8 analysts, the share price prediction for Emcure Pharma is ₹2,229.38 with an upside of 19%.
The PE ratio of Emcure Pharma is 35.11 as of Oct 30, 2026.
The PB ratio of Emcure Pharma is 6.77 as of Oct 30, 2026.
You can view the latest analyst reports on the Emcure Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×